Selank Research Peptide Guide 2026 — Molecular Profile, GABAergic Mechanism & Verification

Selank is a synthetic heptapeptide derived from tuftsin, the immunoglobulin G–derived tetrapeptide Thr-Lys-Pro-Arg. What makes it unusual in the research literature is that it does not appear to work through a single receptor: the published mechanistic work describes at least two distinct molecular actions running in parallel — modulation of GABAergic gene expression and receptor signaling, and direct enzymatic inhibition of the peptidases that degrade endogenous enkephalins. For groups modeling inhibitory neurotransmission, peptidase kinetics, or neuropeptide-immune crosstalk, that dual profile makes Selank a useful probe rather than simply another short peptide.

This guide is written for qualified laboratory researchers sourcing Selank as a research compound. It covers the molecular profile, the mechanism at the pathway, receptor, and enzyme-kinetic level as described in the published literature, representative preclinical data, real citations verifiable through PubMed, in-vitro research applications, how to evaluate the analytical documentation that should accompany a peptide of this class, and the current U.S. regulatory context as of July 2026.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

Selank is a compact, linear seven-residue peptide built on the tuftsin core sequence Thr-Lys-Pro-Arg, extended at the C-terminus by a Pro-Gly-Pro tail. That tail is the defining engineering feature, and it is the same design strategy used in Semax: the extension substantially increases resistance to exopeptidase degradation relative to the parent tetrapeptide, giving Selank a longer functional half-life in experimental systems while preserving the tuftsin recognition motif.

• Compound name: Selank
• Alternative designation: TP-7
• CAS number: 129954-34-3
• Molecular formula: C₃₃H₅₇N₁₁O₉
• Molecular weight: ≈ 751.9 g/mol
• Length: Linear heptapeptide (7 residues)
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
• Parent fragment: Tuftsin (IgG heavy-chain fragment) plus a C-terminal Pro-Gly-Pro tail
• Appearance: White to off-white lyophilized powder; readily water-soluble, reconstituted in aqueous buffer for in-vitro work

Two structural details matter for sourcing. First, Selank is strongly basic: a lysine and an arginine in a seven-residue frame with no acidic residues at all, giving a high net positive charge at physiological pH. That charge state affects reversed-phase retention behaviour, drives the multiply-charged ion distribution on electrospray LC-MS, and makes ion-pairing conditions a meaningful variable in method development.

Second, the three proline residues — at positions 3, 5, and 7 — mean Selank populates cis/trans isomers in solution. This can produce peak broadening or partially resolved shoulder peaks that represent conformers rather than genuine impurities. Reading a Selank HPLC trace correctly therefore requires the mass spectrum alongside it: a shoulder carrying the same mass as the main peak is a conformer, one at a different mass is an impurity.

At roughly 752 g/mol, Selank sits at the small end of the peptide range. A clean protonated-molecule signal near 752 Da, plus the doubly- and triply-charged ions a strongly basic peptide readily forms, is the identity signature to look for.

Section 2 — Mechanism (Pathway Language)

Selank is studied as a multi-target neuropeptide modulator. The published mechanistic literature describes it at the level of enzyme kinetics, receptor signaling, and gene transcription — not at the level of any clinical endpoint.

Enkephalin-degrading enzyme inhibition. The most directly quantified action of Selank is inhibition of the plasma peptidases that hydrolyse endogenous enkephalins. Zozulya and colleagues reported concentration-dependent inhibition of enkephalin hydrolysis in human serum with a micromolar IC₅₀, characterising Selank as more potent in this assay than the reference inhibitors bacitracin and puromycin. Because these enzymes degrade a range of regulatory peptides beyond the enkephalins, this is described as a general mechanism extending the functional lifetime of endogenous peptide signals in a preparation — a directly measurable readout rather than an inferred one.

GABAergic gene expression. Volkova and colleagues reported that Selank administration altered the expression of a large fraction of an 84-gene GABAergic neurotransmission panel in rat frontal cortex, with the response peaking at one hour and partially resolving by three, and with a positive correlation between the Selank-induced and GABA-induced expression profiles. That correlation is the molecular correlate most often cited in support of a GABAergic mode of action.

Receptor-level modulation. Earlier receptor work described Selank as interacting with the benzodiazepine-binding region of the GABA-A receptor complex in rodent preparations, consistent with positive allosteric modulation of GABA-evoked responses. The receptor evidence and the transcriptional evidence are not identical claims, and at least one cell-based study found no direct effect on GABAergic gene mRNA levels in a neuroblastoma line — a negative result discussed in Section 3.

Tuftsin-derived immunomodulatory activity. Retaining the tuftsin recognition motif, Selank is also studied at the neuropeptide-immune interface, where tuftsin analogues are characterised as modulators of cytokine expression profiles in cell-based systems.

This article describes Selank strictly at the enzyme-kinetic, receptor-signaling, and transcriptional level. It is studied for its inhibition of enkephalin-degrading peptidases, its interaction with GABA-A receptor signaling, and its effect on GABAergic gene expression in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical Research Data

The Selank literature spans enzyme-inhibition assays, rodent behavioural pharmacology, targeted qPCR panels, and cell-culture transcriptional work. What distinguishes it from many peptide literatures is a well-documented negative result, which materially improves its interpretive value.

Peptidase inhibition kinetics. The serum enkephalin-hydrolysis work established the quantitative anchor of the mechanistic literature: concentration-dependent inhibition with a micromolar IC₅₀, benchmarked against established peptidase inhibitors in the same assay. This cell-free biochemical readout is among the most directly reproducible endpoints in the Selank literature.

Phenotype-dependent enzymatic response. Follow-on work examined plasma enkephalin-degrading enzyme activity in mice stratified by emotional and stress-reactivity phenotype, reporting that the enzymatic response varied with baseline phenotype — meaning baseline animal or cell-line characteristics materially affect the measured endpoint, and studies that do not control for it are harder to compare.

Targeted GABAergic transcription panels. Kolomin and colleagues reported that a single administration altered mRNA levels of a set of genes by more than two-fold in rat hippocampus — predominantly genes encoding membrane-associated proteins involved in ion homeostasis — while repeated administration produced a distinct, only partially overlapping signature. The transcriptional readout is therefore not stable across exposure schedules, and the schedule must be specified for a result to be interpretable.

Combination pharmacology in a stress model. Kasian and colleagues evaluated Selank alongside diazepam in rats under unpredictable chronic mild stress using the elevated plus maze, reporting a greater effect on the measured behavioural endpoints from the combination than from either compound alone. The mechanistic reading: an additive effect alongside a benzodiazepine is more consistent with complementary pathways than with duplication of benzodiazepine receptor action.

A documented negative result. In IMR-32 neuroblastoma cells, an 84-gene GABAergic panel showed no direct effect of Selank on GABAergic gene mRNA levels. This suggests the transcriptional changes seen in intact rodent tissue may depend on circuit-level or systemic context that a monoculture line does not reproduce. Treat it as a model-selection constraint rather than a contradiction: an in-vivo transcriptional signature should not be assumed to transfer to an immortalised cell line.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Zozulya AA, Neznamov GG, Siuniakov TS, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” PubMed: 11550013 — concentration-dependent inhibition of enkephalin hydrolysis, benchmarked against bacitracin and puromycin.
• “Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions.” 2002. PubMed: 12432865 — phenotype-stratified enzymatic and behavioural response.
• Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology. 2016;7:31 (doi:10.3389/fphar.2016.00031). PMC: PMC4757669 — 84-gene GABAergic panel in rat frontal cortex; time-course and GABA-correlation analysis.
• “GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.” Frontiers in Pharmacology. 2017;8:89 (doi:10.3389/fphar.2017.00089). PubMed: 28293190 — cell-culture study reporting no direct Selank effect on GABAergic gene mRNA in IMR-32 cells.
• Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M. “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.” Behavioural Neurology. 2017;2017:5091027 (doi:10.1155/2017/5091027). PMC: PMC5322660 — elevated plus maze, individual and combined administration.
• Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. Reports on Selank-induced gene expression changes in rat hippocampus, single versus course administration.
• “Semax and Selank Inhibit the Enkephalin-Degrading Enzymes of Human Serum.” Russian Journal of Bioorganic Chemistry (doi:10.1023/A:1011373002885) — comparative peptidase-inhibition characterisation of both Pro-Gly-Pro–extended peptides.

Citing real primary literature is a core part of the PYXAX research-context standard. Two caveats apply specifically to the Selank literature. First, a large share of it originates from a single research lineage in Russian molecular genetics, much of it published in Russian-language journals with limited independent replication outside that group. Second, several frequently repeated mechanistic claims circulating in vendor material — particular receptor affinities, monoamine oxidase selectivity, specific neurotrophin effects — are asserted far more often than they are cited. Verify each claim against a retrievable primary source rather than a secondary summary, including this one.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, Selank is used as a reference and probe compound in several categories of in-vitro and preclinical work:

• Peptidase inhibition assays — as a defined inhibitor in cell-free enkephalin-hydrolysis and neprilysin-family enzyme-kinetic studies.
• GABAergic transcription research — as a stimulus in targeted qPCR panels quantifying GABA receptor subunit and neurotransmission gene expression.
• Allosteric receptor characterisation — as a probe compound in GABA-A binding and modulation studies alongside benzodiazepine reference ligands.
• Neuropeptide stability research — as a model for how C-terminal Pro-Gly-Pro extension alters exopeptidase resistance relative to the parent tetrapeptide.
• Tuftsin structure–activity research — as a defined analogue for comparing the tuftsin motif across neuroactive and immune-facing assay systems.
• Analytical method development — as a strongly basic, proline-rich heptapeptide standard for validating reversed-phase HPLC ion-pairing and electrospray LC-MS identity methods, including resolution of cis/trans conformers from genuine impurities.

Each application is an in-vitro or preclinical research use. Compounds supplied for research must not be used in any human or veterinary context.

Section 6 — How to Evaluate a Source

Selank’s charge state and proline content make its analytical documentation harder to read than that of a neutral peptide, which makes complete documentation more — not less — important.

Step 1 — Confirm the exact molecule and form. The COA should identify the material as Selank (TP-7), give the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, cite CAS 129954-34-3, and report a molecular weight near 752 g/mol. Selank is also supplied as N-acetyl Selank amidate, a distinct molecule with a different mass. Salt form matters too — for a strongly basic peptide, acetate or trifluoroacetate counter-ions affect net peptide content in a stated milligram quantity.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO 17025-accredited facility, and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. A genuine sample should present a protonated-molecule signal consistent with a ~752 g/mol heptapeptide, with the multiply-charged series expected from a strongly basic sequence. A COA reporting only “purity” without an identity mass is incomplete.

Step 4 — Read the chromatogram and the mass spectrum together. HPLC should show a single dominant peak, but for a tri-proline peptide a shoulder is not automatically an impurity. Cross-reference against the mass data: same mass indicates a conformer, different mass indicates a genuine related substance. Deletion sequences — most plausibly a missing proline or a lost terminal residue — are the impurity class worth resolving, visible on mass but easy to miss on purity alone.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical testing event applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For cell-based and enzyme-kinetic work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound sensitive assay systems.

Section 7 — Regulatory Context (July 2026)

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 at the FDA’s White Oak campus to consider a set of peptides for potential inclusion on the Section 503A Bulk Drug Substances List. The docket comprises BPC-157, KPV, TB-500, and MOTS-c on July 23, and emideltide (DSIP), Semax, and Epitalon on July 24.

Selank is not on that docket. This is worth stating precisely, because absence from a review list is frequently misread in both directions. It does not mean Selank has been cleared, endorsed, or approved for any compounding or clinical use, and it equally does not mean Selank has been restricted. It means the compound was not among the seven substances nominated for this review cycle, and its status is unchanged by the outcome of the July meeting.

PCAC recommendations are advisory only and are not final until the FDA issues its own determination. This review concerns pharmacy compounding permissions; it does not constitute FDA approval of any peptide as a pharmaceutical drug. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX FDA peptide reclassification and peptide-compliance landscape guides for the full picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number, matching the COA in the PYXAX COA Library, so researchers can confirm identity — including exact sequence, salt form, and species supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above.

View PYXAX Selank →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.